Bioequivalence between generic tacrolimus products marketed in Spain by adjusted indirect comparison

European Journal of Clinical Pharmacology

Volumn 69, Issue 5, 2013, Pages 1157-1162

  Herranz, Marta ^a   Morales Alcelay, Susana ^a   Corredera Hernández, Ma Teresa ^a   De La Torre Alvarado, José María ^a   Blázquez Pérez, Antonio ^a   Suárez Gea, Ma Luisa ^a   Álvarez, Covadonga ^b   García Arieta, Alfredo ^a  

^a Division de Farmacologia y Evaluacion Clinica   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Bioequivalence; Drug substitution; Generic product; Indirect comparison; Tacrolimus; Therapeutic equivalency

Indexed keywords

GENERIC DRUG; TACROLIMUS;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG MARKETING; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SPAIN;

DRUGS, GENERIC; HUMANS; MODELS, STATISTICAL; SPAIN; TACROLIMUS; THERAPEUTIC EQUIVALENCY;

EID: 84879461018     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1456-6     Document Type: Article

References (25)

1. Real Decreto-ley 9/2011, de 19 de agosto, de medidas para la mejora de la calidad y cohesión del sistema nacional de salud, de contribución a la consolidación fiscal, y de elevación del importe máximo de los avales del Estado para 2011. 9/2011. 19-8-2011. BOE núm 200. 20-9-2011
2. ORDEN SCO/2874/2007, de 28 de septiembre, por la que se establecen los medicamentos que constituyen excepción a la posible sustitución por el farmacéutico con arreglo al artículo 86.4 de la Ley 29/2006, de 26 de julio, de garantías y uso racional de los medicamentos y productos sanitarios. 5-10-2007
3. Meredith PA (2009) Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms. Curr Med Res Opin 25(9):2179-2189
4. Le Corre P (2010) Bioequivalence and generics of index drugs with narrow therapeutic margins. Presse Med 39(2):169-176
5. Committee for Medicinal Products for Human Use (CHMP) (2010) Guideline on the investigation of bioequivalence. European Medicines Agency (EMA), London
6. Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50(6):683-691 (Pubitemid 27341818)
7. Chow SC, Liu JP (2000) Design and analysis of bioavailability and bioequivalence studies, 2nd edn. Marcel Dekker, Inc, New York
8. Chow SC, Liu J (1997) Meta-analysis for bioequivalence review. J Biopharm Stat 7(1):97-111 (Pubitemid 27167937)
9. Welch BL (1947) The generalisation of student's problems when several different population variances are involved. Biometrika 34(1-2):28-35
10. Medicines and Healthcare Products Regulatory Agency. Public Assessment Report Decentralised Procedure UK/H/3029/01-03/DC Tacni 0.5/1/5 mg hard capsules. 28-10-2010. http://www.mhra.gov.uk/home/groups/par/documents/ websiteresources/con103029.pdf. Accessed on 11-2-2012
11. Medicines Evaluation Board in the Netherlands. Public Assessment Report of NL/H/1340/01-03/DC Tacrolimus Sandoz 0.5/1/5 mg hard capsules. 1-2-2010. http://db.cbg-meb.nl/Pars/h102092.pdf. Accessed on 11-2-2012.
12. Medicines Evaluation Board in the Netherlands. Public Assessment Report of NL/H/1332/01-02/DC Tacrolimus Accord 0.5/1 mg hard capsules. 1-10-2010. http://db.cbg-meb.nl/Pars/h102497.pdf. Accessed on 11-2-2012.
13. Yong CJ, Jung LY, Bok JS, Ahyoung LL, Soo PM, Hwan KK (2010) CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study. Ther Drug Monit 32(1):67-72
14. Steiner RW, Feist AA (2011) The "generic" effect of food on tacrolimus pharmacokinetics. Clin Transplant 25:334-335
15. Bekersky I, Dressler D, Boswell GW, Fergen B, Tracewell W, Mekki Q (1998) Bioequivalence of a new strength tacrolimus capsule under development. Transplant Proc 30:1457-1459 (Pubitemid 28309643)
16. Bekersky I, Dressler D, Colburn W, Mekki Q (1999) Bioequivalence of 1 and 5 mg tacrolimus capsules using a replicate study design. J Clin Pharmacol 39:1032-1037 (Pubitemid 30641862)
17. Alloway RR, Isaacs R, Lake K, et al. (2003) Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant 3:1211-1215 (Pubitemid 37214617)
18. Abdulnour HA, Araya CE, Dharnidharka VR (2010) Comparison of generic tacrolimus and Prograf drug levels in a pediatric kidney transplant program: brief communication. Pediatr Transplant 14:1007-1011
19. Lainesse A, Hussain S, Monif T, et al. (2008) Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. Arzneimittelforschung 58:242-247 (Pubitemid 351798784)
20. Park K, Kim YS, Kwon KI, Park MS, Lee YJ, Kim KH (2007) A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults. Clin Ther 29:154-162 (Pubitemid 46414035)
21. Ensor CR, Trofe-Clark J, Gabardi S, McDevitt-Potter LM, Shullo MA (2011) Generic maintenance immunosuppression in solid organ transplant recipients. Pharmacotherapy 31:1111-1129
22. Health Canada, Therapeutic Products Directorate. Guidance for Industry. Bioequivalence Requir: Crit Dose Drugs. 31-5-2006
23. CHMP efficacy working party therapeutic subgroup on pharmacokinetics (EWP-PK). Questions & Answers: Positions on specific questions addressed to the EWP therapeutic subgroup on Pharmacokinetics. EMA/618604/2008 Rev. 2. 22-7-2010. London, EMEA. Accessed on 11-2-2012
24. Mathew P, Mandal J, Patel K, Soni K, Tangudu G, Patel R, Kale P (2011) Bioequivalence of two tacrolimus formulations under fasting conditions in healthy male subjects. Clin Ther 33(9):1105-1119
25. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, Bradburn M, Eastwood AJ (2005) Indirect comparisons of competing interventions. Health Technol Assess 9(26):1-iv